Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TRDA
TRDA logo

TRDA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Entrada Therapeutics Inc (TRDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.090
1 Day change
4.11%
52 Week Range
16.450
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

TRDA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some bullish technical momentum in the short term, but the broader trend is still weak, analyst sentiment has turned mixed-to-negative after disappointing cohort data, insider selling has increased sharply, and there is no recent news or financial confirmation to support an immediate long-term entry. Given the investor profile and impatience, this is not a clear buy today.

Technical Analysis

Current price is 6.38, slightly above the pivot at 6.483 but still below the key near-term resistance zone at 7.01. MACD histogram is positive and expanding, which supports short-term momentum, but RSI_6 at 43.25 is neutral and does not confirm strong strength. The moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer trend is still down. Overall, the technical picture is mixed: short-term rebound potential exists, but the primary trend is not yet reversed. Similar-pattern stats also point to slight negative forward drift over the next week and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment looks very bullish on paper because the put-call open interest ratio is extremely low at 0.08, showing heavy call dominance. However, option volume is 0, so there is no active trading confirmation today. Implied volatility is extremely elevated (IV 30d at 660.36, IV percentile 100, IV rank 118.16), which is consistent with a highly speculative biotech name and suggests the options market is pricing in a major event risk rather than stable conviction.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
6

Positive Catalysts

  • ["MACD histogram is positive and expanding, suggesting improving short-term momentum.", "Roth Capital still keeps a Buy rating despite cutting its target to $10.", "Oppenheimer raised its target to $23 and kept an Outperform rating, citing platform potential.", "Cantor Fitzgerald initiated coverage with an Overweight rating, viewing the delivery platform as potentially differentiated."]

Neutral/Negative Catalysts

  • ["Roth Capital cut price target sharply to $10 from $19 after lackluster Cohort 1 dystrophin results.", "H.C. Wainwright downgraded the stock to Neutral from Buy after underwhelming initial cohort data.", "No news in the recent week, so there is no fresh catalyst driving the shares today.", "Insiders are selling, and selling increased 1842.13% over the last month.", "Hedge funds are neutral with no significant accumulation trend over the last quarter.", "Bearish moving-average structure remains intact.", "Historical pattern data suggests slight negative returns over the next week and month."]

Financial Performance

Financial snapshot data was unavailable due to an error, so there is no reliable latest-quarter revenue or earnings update to assess. Because this appears to be a clinical-stage biotech, the investment case is driven more by pipeline/readout progress than by conventional operating growth. The latest identifiable season in the provided analyst commentary is 2026 Q2-related readout discussion ahead of upcoming cohort data, but no actual quarter financials were provided.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed but has weakened recently. Positive views remain from Oppenheimer (Outperform, target raised to $23) and Cantor Fitzgerald (Overweight initiation), while near-term confidence has deteriorated with Roth Capital cutting its target to $10 and H.C. Wainwright downgrading to Neutral after underwhelming cohort data. Wall Street’s bull case is that Entrada’s delivery platform could still be differentiated and drive meaningful upside on better follow-up data. The bear case is that early efficacy signals have not been convincing enough, and the recent readout raised doubts versus competitors.

Wall Street analysts forecast TRDA stock price to rise
4 Analyst Rating
Wall Street analysts forecast TRDA stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.810
sliders
Low
13
Averages
16.5
High
20
Current: 6.810
sliders
Low
13
Averages
16.5
High
20
Roth Capital
Buy
downgrade
$19 -> $10
AI Analysis
2026-05-08
Reason
Roth Capital
Price Target
$19 -> $10
AI Analysis
2026-05-08
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a Buy rating on the shares. The Phase 1/2 study Cohort 1 results of ENTR-601-44 in DMD44 patients produced "lackluster dystrophin expression," says the analyst, who looks forward to Cohort 2 results expected by year-end but is "unsure" whether Cohort 2 data would outperform Novartis' (NVS) Del-zota.
H.C. Wainwright
Raghuram Selvaraju
Buy
to
Neutral
downgrade
2026-05-08
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
2026-05-08
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics to Neutral from Buy without a price target saying the ELEVATE-44-201 initial cohort data \"underwhelm.\" The functional data appear more encouraging, but they are early, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TRDA
Unlock Now

People Also Watch